<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SPTLC1 - Serine Palmitoyltransferase</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>SPTLC1</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>SPTLC1 - Serine Palmitoyltransferase</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=SPTLC1" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic lateral sclerosis</a>, <a href="/wiki/juvenile-amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Juvenile amyotrophic lateral sclerosis</a>, <a href="/wiki/neuropathy" style="color:#ef9a9a">Neuropathy</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-58e655ee" style="color:#ce93d8" title="Score: 0.57">APOE-Mediated Synaptic Lipid Raft Stabil...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">25 edges</a></td>
</tr>
</table>
Sptlc1 Serine Palmitoyltransferase plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Serine Palmitoyltransferase Long Chain Base Subunit 1 (SPTLC1) is a critical gene encoding one of two core subunits of the serine palmitoyltransferase (SPT) enzyme complex, which catalyzes the foundational step in de novo sphingolipid biosynthesis. Located on chromosome 9q22.31, the SPTLC1 protein is ubiquitously expressed but plays particularly important roles in the nervous system due to the high abundance of sphingolipids in neuronal membranes and myelin sheaths. The gene product forms a heterodimeric complex with SPTLC2 (the long chain base subunit 2) to create the functional enzyme, which is located in the endoplasmic reticulum (ER) of cells [1](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154093/). [@hannun2008]
Sphingolipids constitute a major class of membrane lipids that are essential for cellular structure, signaling, and function. Beyond their structural roles, sphingolipids and their metabolites serve as crucial signaling molecules involved in cell growth, differentiation, [apoptosis](/entities/apoptosis), and stress responses. The proper regulation of sphingolipid metabolism is therefore fundamental to cellular homeostasis, and disruptions in this pathway have been implicated in numerous pathological conditions, particularly neurodegenerative diseases [2](https://www.jbc.org/article/S0021-9258(20)30157-8/fulltext). [@online]
This page provides comprehensive information about SPTLC1, including its molecular structure, enzymatic function, physiological significance, and its involvement in human disease pathogenesis. [@yard2011]
--- [@mccampbell2010]
The SPTLC1 gene (Gene ID: 10574) spans approximately 21 kilobases and is organized into multiple exons that encode the 473-amino acid protein product. The gene is located on the long arm of chromosome 9 at position 22.31 (9q22.31), a region that has been implicated in various neurological disorders [3](https://www.omim.org/entry/605712). The genomic context of SPTLC1 includes several neighboring genes involved in lipid metabolism, reflecting the evolutionary clustering of lipid-related enzymes. [@hojjati2020]
The SPTLC1 protein (UniProt ID: O15269) possesses several distinct structural features that facilitate its enzymatic function. The protein contains a pyridoxal 5'-phosphate (PLP)-binding domain, which is essential for the decarboxylative condensation reaction catalyzed by serine palmitoyltransferase. PLP, the active form of vitamin B6, serves as a cofactor that forms a Schiff base intermediate with the substrate serine, enabling the condensation reaction with palmitoyl-CoA [4](https://www.sciencedirect.com/science/article/pii/S0092867410300978). [@brown1997]
The SPTLC1 subunit interacts with SPTLC2 to form a functional heterodimer, although higher-order oligomers have been reported. The interface between these subunits is critical for enzyme stability and catalytic activity. Mutations that disrupt this interaction can lead to loss of function or altered substrate specificity, resulting in human disease phenotypes [5](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3885832/). [@breslow2010]
--- [@simpson2003]
Serine palmitoyltransferase (SPT) functions as the rate-limiting enzyme in the de novo synthesis of sphingolipids. The canonical reaction catalyzed by SPT involves the condensation of L-serine with palmitoyl-CoA (C16:0) to produce 3-ketosphinganine, which is subsequently reduced to sphinganine (dihydrosphingosine) by 3-ketosphinganine reductase. This pathway represents the first and committed step in sphingolipid biosynthesis, making SPT a critical regulatory point [1](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154093/). [@bode2016]
The reaction mechanism involves several key steps: [@ref]
While palmitoyl-CoA is the preferred acyl-CoA substrate, SPT can also utilize other fatty acyl-CoAs of varying chain lengths (C14-C18), leading to the production of atypical sphingoid bases. The substrate specificity is influenced by the composition of the SPTLC1/SPTLC2 heterodimer and by regulatory mechanisms that sense cellular lipid status [6](https://www.jlr.org/article/S0022-2275(20)42158-1/fulltext).
Sphingolipids synthesized through the SPT pathway serve multiple essential functions:
Cellular Membrane Structure: Sphingolipids, particularly ceramide and complex gangliosides, are enriched in lipid rafts—dynamic membrane microdomains that organize signaling complexes and facilitate membrane protein function. In [neurons](/entities/neurons), gangliosides are abundant in synaptic membranes and are critical for neurotransmission and synaptic plasticity.
Myelin Formation: The central and peripheral nervous systems contain high concentrations of sphingolipids, particularly galactosylceramide and sulfatide, which are essential for the formation and maintenance of myelin sheaths. Dysregulation of sphingolipid metabolism can lead to demyelinating disorders.
Cell Signaling: Ceramide, sphingosine-1-phosphate (S1P), and other sphingolipid metabolites function as bioactive signaling molecules that regulate cell survival, proliferation, differentiation, and apoptosis. The so-called "sphingolipid rheostat" refers to the balance between pro-apoptotic ceramide/sphingosine and pro-survival S1P, which determines cellular fate decisions.
Protein Trafficking: Sphingolipids participate in the formation of vesicular transport carriers and the sorting of proteins through the secretory and endocytic pathways. The lipid composition of membrane compartments influences cargo selection and vesicle budding.
The expression of SPTLC1 is subject to transcriptional regulation by various nuclear receptors and transcription factors involved in lipid metabolism. Sterol regulatory element-binding proteins (SREBPs) activate the transcription of genes involved in cholesterol and fatty acid biosynthesis, and evidence suggests that SPTLC1 expression may be influenced by SREBP signaling to coordinate membrane lipid synthesis with sterol availability [7](https://www.sciencedirect.com/science/article/pii/S0092867410300978).
SPT activity is modulated by several post-translational mechanisms, including phosphorylation and interaction with regulatory proteins. The ORMDL family of ER membrane proteins (ORMDL1, ORMDL2, and ORMDL3) serve as negative regulators of SPT activity, forming a complex that sense and respond to changes in sphingolipid levels. When sphingolipid concentrations are high, ORMDL proteins inhibit SPT to prevent excessive accumulation, while during periods of sphingolipid depletion, this inhibition is relieved to restore metabolic flux [8](https://www.nature.com/articles/ncomms2199).
Serine palmitoyltransferase localizes to the endoplasmic reticulum (ER), where sphingolipid biosynthesis is initiated. The ER membrane provides an environment conducive to the interaction between the enzyme and its substrates, which include acyl-CoAs derived from fatty acid synthesis and serine imported from the cytosol. The subcellular localization of SPT ensures proper channeling of metabolic intermediates through the sphingolipid biosynthesis pathway.
Mutations in SPTLC1 were first identified as causes of hereditary spastic paraplegia type 17 (HSP17), an autosomal dominant disorder characterized by progressive lower limb spasticity and weakness. The initial discovery of SPTLC1 mutations in HSP patients highlighted the importance of sphingolipid metabolism in neuronal function and axonal integrity [9](https://academic.oup.com/brain/article/130/10/2594/325845).
Subsequent studies have identified multiple pathogenic variants in SPTLC1 that cause HSP, including missense mutations that alter enzyme function or substrate specificity. These mutations often result in increased production of atypical sphingoid bases, such as 1-deoxysphinganine, which can be toxic to neurons. The accumulation of deoxysphingolipids is thought to disrupt ER homeostasis, impair calcium handling, and activate stress response pathways that ultimately lead to axonal degeneration [10](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940903/).
Interestingly, some SPTLC1 mutations causing HSP exhibit incomplete penetrance, suggesting that modifier genes or environmental factors influence disease expression. The identification of SPTLC1 as an HSP gene has provided insights into the pathogenesis of other neurodegenerative conditions characterized by axonal dysfunction.
Emerging evidence links SPTLC1 to the pathogenesis of amyotrophic lateral sclerosis (ALS), a rapidly progressive neurodegenerative disease affecting upper and lower motor neurons. Whole-exome sequencing studies have identified rare variants in SPTLC1 in patients with familial ALS, although the pathogenicity of these variants remains to be fully characterized [11](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5812048/).
The connection between SPTLC1 and ALS may relate to the role of sphingolipids in maintaining motor neuron health. Sphingolipid metabolism influences mitochondrial function, oxidative stress responses, and excitotoxicity—all processes implicated in ALS pathogenesis. Furthermore, alterations in membrane lipid composition could affect the stability of the neuromuscular junction, the site where motor neurons communicate with muscle fibers.
While direct mutations in SPTLC1 are not a common cause of [Alzheimer's disease](/diseases/alzheimers-disease), dysregulation of sphingolipid metabolism is increasingly recognized as a feature of Alzheimer's disease neuropathology. The SPT-catalyzed reaction produces sphingolipid intermediates that are subsequently metabolized to [amyloid-beta](/proteins/amyloid-beta) (Aβ) precursors and other lipid species that accumulate in the Alzheimer's brain.
Studies have demonstrated alterations in sphingolipid profiles in Alzheimer's disease patients, including decreased ceramide levels and changes in ganglioside composition. These changes may affect [amyloid precursor protein](/entities/app-protein) (APP) processing, Aβ aggregation, and synaptic function. The involvement of SPTLC1 in these processes suggests that targeting sphingolipid metabolism could represent a therapeutic strategy for Alzheimer's disease [12](https://www.j-alz.com/articles/200427).
[Parkinson's disease](/diseases/parkinsons-disease), the second most common neurodegenerative disorder, has also been linked to alterations in sphingolipid metabolism. Post-mortem studies of Parkinson's disease brains reveal elevated ceramide levels in substantia nigra dopaminergic neurons, which may contribute to apoptotic cell death. Furthermore, mutations in genes involved in glycosphingolipid metabolism, such as [GBA](/entities/gba) (glucocerebrosidase), are established risk factors for Parkinson's disease, highlighting the importance of lipid pathways in disease pathogenesis.
The potential involvement of SPTLC1 in Parkinson's disease may relate to its role in generating lipid species that regulate [alpha-synuclein](/proteins/alpha-synuclein) aggregation and toxicity. Sphingolipids can interact with alpha-synuclein and influence its membrane binding, oligomerization, and fibril formation. Understanding how SPTLC1 activity affects these processes could provide new insights into Parkinson's disease mechanisms [13](https://www.sciencedirect.com/science/article/pii/S0014575512005373).
Beyond neurodegenerative diseases, SPTLC1 and the broader sphingolipid biosynthesis pathway have been implicated in metabolic disorders, cancer, and inflammatory conditions. The dysregulation of sphingolipid metabolism contributes to insulin resistance, obesity, and cardiovascular disease. In cancer, certain tumor cells exhibit altered SPT expression and dependency on de novo sphingolipid synthesis for survival and proliferation, making SPT a potential therapeutic target.
SPTLC1 interacts with several proteins that regulate its activity, localization, and function:
SPTLC1 occupies a central position in lipid metabolism, connecting fatty acid metabolism to complex sphingolipid synthesis. The pathway branches from SPT-generated sphingoid bases to produce:
Given the involvement of SPTLC1 in multiple diseases, there is significant interest in developing therapeutic modulators of SPT activity. Small molecule inhibitors of SPT, such as myriocin and fingolimod (FTY720), have been used in research and clinical settings. Myriocin is a potent fungal toxin that irreversibly inhibits SPT and has been investigated for its immunosuppressive and anti-cancer properties. Fingolimod, a SPT substrate analog, is approved for treating multiple sclerosis and exerts its effects by modulating sphingosine-1-phosphate receptor signaling.
For hereditary spastic paraplegia caused by SPTLC1 mutations, approaches aimed at reducing the production of toxic deoxysphingolipids are being explored. These include dietary supplementation with serine (to promote canonical substrate utilization) and pharmacological inhibition of SPT to limit abnormal metabolite production.
Ongoing research aims to:
Sptlc1 Serine Palmitoyltransferase plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Sptlc1 Serine Palmitoyltransferase has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
The following diagram shows the key molecular relationships involving SPTLC1 - Serine Palmitoyltransferase discovered through SciDEX knowledge graph analysis: